Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, January 25, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Lewis Maintained (ABT) at Buy with Increased Target to $70 on, Jan 25th, 2018
David Lewis of Morgan Stanley, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $67 to $70 on, Jan 25th, 2018.
David has made no other calls on ABT in the last 4 months.
There are 3 other peers that have a rating on ABT. Out of the 3 peers that are also analyzing ABT, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Sean Lavin of "BTIG" Downgraded from Strong Buy to Hold on, Monday, January 22nd, 2018
- Amit Hazan of "Citigroup" Maintained at Hold with Increased Target to $59 on, Thursday, October 19th, 2017
This is the rating of the analyst that currently disagrees with David
- Vijay Kumar of "Evercore ISI Group" Initiated at Buy and Held Target at $64 on, Wednesday, January 3rd, 2018
